BELVIQ CIV

Select the drug indication to add to your list

BELVIQ

Obesity
Only 4 drugs may be compared at once

Generic Name and Formulations:

Lorcaserin HCl 10mg; tabs.

Select therapeutic use:

Indications for BELVIQ:

As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30kg/m2 or ≥27kg/m2 in the presence of at least one weight-related comorbidity (eg, hypertension, dyslipidemia, type 2 diabetes).

Limitations Of use:

Safety and efficacy of coadministration with other weight loss products (eg, phentermine, OTC drugs, herbal preps) have not been established. Effect on cardiovascular morbidity and mortality has not been established.

Adult:

Max: 10mg twice daily. Evaluate weight loss after 12 weeks. Discontinue if ≥5% weight loss is not achieved.

Children:

<18yrs: not recommended.

Contraindications:

Pregnancy.

Warnings/Precautions:

Monitor for serotonin syndrome or neuroleptic malignant syndrome-like signs/symptoms; discontinue and treat if occur. CHF. Risk of valvular heart disease; evaluate and consider discontinuing if signs/symptoms occur. Bradycardia or >1st degree heart block. Monitor for depression, suicidal thoughts, and/or unusual behavioral changes; discontinue if develop. Increased risk of hypoglycemia in patients with diabetes on antidiabetic therapy; measure blood glucose prior to starting and during treatment. Predisposition to priapism. Anatomical penile deformation. Monitor CBCs periodically during therapy. Measure prolactin levels if elevation is suspected. Moderate renal impairment. Severe renal impairment or ESRD: not recommended. Severe hepatic impairment. Nursing mothers: not recommended.

Interactions:

Caution with concomitant triptans, MAOIs, linezolid, SSRIs, SNRIs, TCAs, bupropion, lithium, tramadol, tryptophan, St. John’s wort, antipsychotics, dopamine antagonists, or PDE-5 inhibitors. Potentiates dextromethorphan and other CYP2D6 substrates. Increased risk of cardiac valvulopathy with concomitant drugs that are potent 5-HT2B receptor agonists (eg, cabergoline). Concomitant insulin: not studied.

See Also:

BELVIQ XR

Pharmacological Class:

Serotonin 2C receptor agonist.

Adverse Reactions:

Headache, dizziness, fatigue, nausea, dry mouth, constipation, hypoglycemia, back pain, cough; cognitive impairment, bradycardia, psychiatric disorders, hematological changes, prolactin elevation.

Generic Availability:

NO

How Supplied:

Tabs—60; XR tabs—30

BELVIQ 10mg tablets (Qty:60)

appx. price $279.00